Product Description
CDFR0209, a combination of an immediate-release formulation of omeprazole 40 mg and sodium bicarbonate 1100 mg, has been developed to treat acid-related disorders. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28111929/)
Mechanisms of Action: Proton Pump Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ajou University School of Medicine
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Gastroesophageal Reflux|Stomach Ulcer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02710994 |
MED-CT1-14-085 | P1 |
Completed |
Stomach Ulcer|Gastroesophageal Reflux |
2014-08-01 |
2019-03-20 |
Recent News Events
Date |
Type |
Title |
|---|